{"id":448964,"title":"Guidance Policy - Use of Positron Emitting Radiopharmaceuticals (PERs) in Basic Research Policy (POL-0053) - Canada.ca","sourceCode":"hc","sourceName":"Health Canada","language":"en","captureDate":"2026-01-03","captureTimestamp":"2026-01-03T18:07:00.461000+00:00","jobId":6,"originalUrl":"https://www.canada.ca/en/health-canada/services/drugs-health-products/compliance-enforcement/information-health-product/drugs/guidance-policy-use-positron-emitting-radiopharmaceuticals-basic-research-0053.html?wbdisable=false","snippet":"Guidance Policy - Use of Positron Emitting Radiopharmaceuticals (PERs) in Basic Research Policy (POL-0053) (February 24, 2006) Contact Name: Drug GMP Inspection Unit Tel: 613-952-9319 Fax: 613-957-6709 E-Mail: GMP_Questions_BPF@hc-sc.gc.ca (PDF Version - 112 K) Health Products…","rawSnapshotUrl":"/api/snapshots/raw/448964","browseUrl":"https://replay.healtharchive.ca/job-6/20260103180700/https://www.canada.ca/en/health-canada/services/drugs-health-products/compliance-enforcement/information-health-product/drugs/guidance-policy-use-positron-emitting-radiopharmaceuticals-basic-research-0053.html?wbdisable=false#ha_snapshot=448964","mimeType":"text/html","statusCode":200,"captureBackend":"browsertrix","captureFidelity":"high"}